Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former Valeant, Philidor Execs Charged With Elaborate Kickback Scheme

Executive Summary

Specialty mail-order pharmacy Philidor was held up as an example of how Valeant was bilking patients when the usually close arrangement initially came to light; now it seems that Valeant itself was allegedly getting bilked.

You may also be interested in...



Bausch Health Boosts Ad Spending For Expanding OTC Eye Care Lineup

"We're investing more to drive growth as we allocate capital to support the launches of new products in the segment like Lumify, for DTC advertising that continue to drive sales growth of other US consumer products like our eye vitamins," says CEO Joseph Papa.

Bausch Health Boosts Ad Spending For Expanding OTC Eye Care Lineup

"We're investing more to drive growth as we allocate capital to support the launches of new products in the segment like Lumify, for DTC advertising that continue to drive sales growth of other US consumer products like our eye vitamins," says CEO Joseph Papa.

Bausch Health Boosts Ad Spending For Expanding Supplement Lineup

Canadian firm, recently renamed from Valeant Pharmaceuticals International, includes launches of Ocuvite Blue Light and PreserVision AREDS 2 Formula Chewable vitamins among its reasons for increasing its consumer health advertising spending. Q2 revenues for its consumer health segment were up 5% organically to $369m.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel